

# Q1 2018 RESULTS

## NET COMPANY SALES & BUSINESS EPS

€7,898M

Q1 2018 SALES

€1.28

Q1 2018 BUSINESS EPS

## NET SALES BY GLOBAL BUSINESS UNIT



GENERAL MEDICINES & EMERGING MARKETS €3,401M



SANOFI GENZYME (SPECIALTY CARE) €1,460M



CONSUMER HEALTHCARE €1,238M




DIABETES & CARDIOVASCULAR €1,088M



SANOFI PASTEUR (VACCINES) €711M

## SALES BY GEOGRAPHY



\*Note that image is illustrative only. Rest of the World: Japan, South Korea, Canada, Australia, New Zealand and Puerto Rico. Eurasia: Russia, Ukraine, Georgia, Belarus, Armenia and Turkey

## R&D HIGHLIGHTS



74

projects in development for NMEs or additional indications



28

projects in advanced clinical trial

